Searchable abstracts of presentations at key conferences in endocrinology

ea0035p224 | Clinical case reports Pituitary/Adrenal | ECE2014

Cushing's disease in patient with primary empty sella

Kurowska Maria , Malicka Joanna , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: The empty sella syndrome (ESS) is defined as the penetration of the subarachnoid space into intrasellar region. In ESS pituitary hormonal function is usually normal, but several, mostly subtle, hormonal abnormalities have been also reported. The coexistence of Cushing’s disease and primary empty sella is very rare.Objective: The presentation of an exceptional case of a patient with Cushing’s disease associated with primary empty s...

ea0035p225 | Clinical case reports Pituitary/Adrenal | ECE2014

Temozolomide-induced marked regression of invasive Crooke's cells corticotropinoma in patient with Cushing's disease

Kurowska Maria , Malicka Joanna , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: Crooke’s cells are normal corticotrophs with cytoplasmic accumulation of cytokeratin filaments in response to glucocorticoids excess. Crooke’s cell corticotropinomas are the unique cause of Cushing’s disease. Nearly all of them are invasive macroadenomas, generally aggressive, refractory to conventional therapy, with high recurrence rate.Aim of the study was to present a case study of a patient with Cushing’s disease cau...

ea0035p226 | Clinical case reports Pituitary/Adrenal | ECE2014

Treatment of aggressive corticotropinoma with temozolomide and bevacizumab in patient with Nelson's syndrome

Malicka Joanna , Kurowska Maria , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: Aggressive corticotropinomas are more invasive than other pituitary tumors. Recent reports have documented the efficacy of temozolomide alone or in combination with an anti-angiogenic agent –bevacizumab in invasive pituitary adenomas treatment.Objective: Presentation a case of 56-year-old woman initially diagnosed as Cushing’s disease and the analysis of treatment procedures with special concentration on temozolomide and bevacizum...